Real-world data for predictors of PSA response to Lu177-PSMA-617 in metastatic castration resistant prostate cancer

被引：0
|
作者：
Hassoun, Rebecca [1 ]
Tann, Mark [1 ]
Sims, Justin [1 ]
Auxier, Ashleigh [1 ]
Althouse, Sandra K. [1 ]
King, Jennifer [1 ]
Adra, Nabil [1 ]
机构：
[1] Indiana Univ, Simon Comprehens Canc Ctr, Indianapolis, IN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e17044
引用
收藏
页数：1
相关论文
共 50 条
  • [31] 177Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer
    Sanli, Yasemin
    Simsek, Duygu Has
    Sanli, Oner
    Subramaniam, Rathan M.
    Kendi, Ayse Tuba
    BIOMEDICINES, 2021, 9 (04)
  • [32] Real-world clinical outcomes of patients treated with Lu-177-PSMA-617 for metastatic castration-resistant prostate cancer (mCRPC): A single-institution experience.
    Grijalva, Valeria Maldonado
    Wang, John
    Nedrud, Marybeth
    Kelleher, Colm
    Wong, Terence Z.
    Labriola, Matthew
    McManus, Hannah Dzimitrowicz
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 83 - 83
  • [33] 225Ac-PSMA-617/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience
    Fadi Khreish
    Niklas Ebert
    Martin Ries
    Stephan Maus
    Florian Rosar
    Hendrik Bohnenberger
    Tobias Stemler
    Matthias Saar
    Mark Bartholomä
    Samer Ezziddin
    European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47 : 721 - 728
  • [34] Excellent Response to Lower Dose of 177Lu-PSMA-617 in a Metastatic Castration-Resistant Prostate Cancer Patient With a Transplanted Kidney
    Norouzi, Ghazal
    Aghdam, Ramin Akbarian
    Hashemifard, Hamidreza
    Pirayesh, Elahe
    CLINICAL NUCLEAR MEDICINE, 2019, 44 (06) : 483 - 484
  • [35] Response to Concomitant Enzalutamide and 177Lu-PSMA-617 Radioligand Therapy in ATM-Mutated Metastatic Castration Resistant Prostate Cancer
    Satapathy, Swayamjeet
    Das, Chandan Krushna
    Parihar, Ashwin Singh
    Sood, Ashwani
    Mittal, Bhagwant R.
    CLINICAL NUCLEAR MEDICINE, 2021, 46 (07) : 582 - 583
  • [36] Response and tolerability after a single dose of Lu-177-PSMA-617 in patients with metastatic castration resistant prostate cancer: a multicenter Study
    Rahbar, Kambiz
    Schmidt, Matthias
    Heinzel, Alexander
    Eppard, Elisabeth
    Yordanova, Anna
    Claesener, Michael
    Bode, Axel
    Ahmadzadehfar, Hojjat
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57
  • [37] 225Ac-PSMA-617/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience
    Khreish, Fadi
    Ebert, Niklas
    Ries, Martin
    Maus, Stephan
    Rosar, Florian
    Bohnenberger, Hendrik
    Stemler, Tobias
    Saar, Matthias
    Bartholomae, Mark
    Ezziddin, Samer
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (03) : 721 - 728
  • [38] 177Lu-PSMA-617 for metastatic prostate cancer in India
    Ghose, Aruni
    Banerjee, Soirindhri
    Choudhury, Partha S.
    Maniam, Akash
    Gupta, Manoj
    Banna, Giuseppe L.
    Vasdev, Nikhil
    Ghose, Amit
    Noronha, Vanita
    Mitra, Swarupa
    LANCET REGIONAL HEALTH - SOUTHEAST ASIA, 2024, 30
  • [39] SPECT/CT in Early Response Assessment of Patients with Metastatic Castration-Resistant Prostate Cancer Receiving 177Lu-PSMA-617
    Demirci, Ridvan Arda
    Gulati, Roman
    Hawley, Jessica E.
    Yezefski, Todd
    Haffner, Michael C.
    Cheng, Heather H.
    Montgomery, Robert B.
    Schweizer, Michael T.
    Yu, Evan Y.
    Nelson, Peter S.
    Chen, Delphine L.
    Iravani, Amir
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65 (12) : 1945 - 1951
  • [40] Re: Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
    Hadaschik, Boris
    Herrmann, Ken
    EUROPEAN UROLOGY, 2021, 80 (04) : 520 - 521
12345